Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: A pilot study

Urakami, Shinji; Yoshino, Tomoyuki; Kikuno, Nobuyuki; Imai, Shin; Honda, Satoshi; Yoneda, Tatuaki; Kishi, Hirofumi; Shigeno, Kazushi; Shiina, Hìroaki; Igawa, Mikio

doi:10.1016/j.urology.2004.10.033

Cited by 22 publications

(14 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…weekly, 10 mg/m 2 estramustine phosphate orally daily, and carboplatin i.v. to an area under the curve of 6 on day 1 of every 4-week cycle (17,18). In addition, prostatic biopsy specimens of another consecutive 19 HRPC cases (median age 78.0 years, range 67-80 years) who were not exposed to taxane-based chemotherapy as proper controls for HRPC treated with taxane-based chemotherapy were also examined for Bcl-2, Bak, and Bax expression at the time of HRPC diagnosis between January 1995 and December 2001; all of these specimens showed viable cancer cells.…”

Section: Methodsmentioning

confidence: 99%

“…Progressive disease was defined as progression of PSA levels, measurable or osseous lesions, or worsened pathologic findings. In addition, these response criteria have been used in our recent reports associated with HRPC (17,18). Time to progression was measured from the first day of treatment to the offstudy data or progressive disease.…”

Section: Methodsmentioning

confidence: 99%

“…Unfortunately, no definite treatment modalities have been available for HRPC until these days. However, we have reported that taxanebased chemotherapy was effective against some cases of HRPC (17,18). In addition, most recently, two pivotal multicenter phase III randomized clinical trials, TAX 327 and Southwest Oncology Group 9916, have shown a survival advantage of HRPC treated with taxane-based chemotherapy (19,20).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Bcl-2 Expression as a Predictive Marker of Hormone-Refractory Prostate Cancer Treated with Taxane-Based Chemotherapy

Yoshino

Shiina

Urakami

et al. 2006

Clinical Cancer Research

Self Cite

139

100

View full text Add to dashboard Cite

Purpose: Bcl-2 inhibits apoptosis, and its overexpression is associated with hormone refractory prostate cancer (HRPC). Bak and Bax are in the Bcl-2 family and counteract the antiapoptotic function of Bcl-2. Taxane-induced (paclitaxel and its analogue docetaxel) phosphorylation of Bcl-2 abolishes the potential antiapoptotic effect of Bcl-2. We hypothesized that (a) survival benefit in HRPC patients treated with taxanes is determined by the presence of Bcl-2 protein and (b) altered expression of Bak and Bax protein caused by genetic mutation is associated with biological aggressiveness of prostate cancer. Experimental Design: Forty localized prostate cancer and 30 HRPC cases were used in this study. Surgical specimens of localized prostate cancer and biopsy specimens of HRPC were used for immunostaining of Bcl-2, Bak, and Bax as well as DNA extraction. Mutations in the Bak and Bax genes were screened by single-strand conformational polymorphism, and confirmed by direct DNA sequencing. Results: Bcl-2^positive HRPC showed longer cause-specific survival in comparison with the counterparts. Multivariate analysis revealed that the level of Bcl-2 expression before treatment with taxane-based chemotherapy was an independent predictor for cause-specific survival (P < 0.01) and baseline prostate-specific antigen level was an independent predictor for progression-free survival (P < 0.01). Bax gene mutation was found in only one HRPC specimen.Conclusions: Bcl-2 expression in addition to prostate-specific antigen measurement before treatment could identify HRPC patients who may benefit from taxane-based chemotherapy. Mutation of the Bak and Bax genes is a rare event in prostate cancer.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Bcl-2 Expression as a Predictive Marker of Hormone-Refractory Prostate Cancer Treated with Taxane-Based Chemotherapy

Yoshino

Shiina

Urakami

et al. 2006

Clinical Cancer Research

Self Cite

139

100

View full text Add to dashboard Cite

show abstract

“…Single agent docitaxel also resulted in a median survival of 18 months. Docitaxel based regimens are now the standard for HRPC [22].…”

Section: Hormone Resistant Prostate Cancermentioning

confidence: 99%

Prostate Cancer - What's New?

Doddamani

Kayastha

2008

Medical Journal Armed Forces India

View full text Add to dashboard Cite

Research has shown that prostate specific antigen (PSA) is a tumour marker for diagnosis of cancer prostate with significant prognostic value. Screening studies in North America and Europe have revealed that carcinoma prostate is common. Early detection and treatment improves the quality of life besides preventing deaths due to metastatic prostate cancer. Radical prostatectomy and laparoscopic radical prostatectomy has become the standard treatment for localized prostate cancer in all major uro-oncological centres resulting in reduced mortality.

show abstract

“…In castration-resistant prostate cancer, phase II and III trials have shown that docetaxel combined with either prednisone or estramustine, given as frontline chemotherapy in patients with castration-resistant prostate cancer, is superior to mitoxantrone combined with the same agents in terms of overall survival, time to disease progression, pain control and PSA response [9][10][11][12]. With a median time to PSA progression reaching 6-8 months, the need to evaluate further systemic treatments in the second-line setting is justified [13].…”

Section: Introductionmentioning

confidence: 99%

Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study

Kentepozidis

Soultati

Giassas

et al. 2012

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: A pilot study

Cited by 22 publications

References 17 publications

Bcl-2 Expression as a Predictive Marker of Hormone-Refractory Prostate Cancer Treated with Taxane-Based Chemotherapy

Bcl-2 Expression as a Predictive Marker of Hormone-Refractory Prostate Cancer Treated with Taxane-Based Chemotherapy

Prostate Cancer - What's New?

Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study

Contact Info

Product

Resources

About